Genmab and BioNTech to collaborate on new cancer candidate; Small Australian biotech sees hope in brain metastases trial

Two European biotechs are upping the ante on their collaboration.

Genmab and BioNTech will expand their relationship to develop and potentially commercialize new immunotherapies for the treatment of cancer. The companies will work jointly on research, development and then commercialization of the monospecific antibody candidates for various cancer indications.


Click to view original post